| Great Lakes Healthcare Center | |
| 2300 Great Lakes Dr, Dyer, Indiana 46311 | |
| (219) 322-3555 | |
| Name | Great Lakes Healthcare Center |
|---|---|
| Location | 2300 Great Lakes Dr, Dyer, Indiana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 134 |
| Occupancy Rate | 73.21% |
| Medicare ID (CCN) | 155218 |
| Legal Business Name | Hancock Regional Hospital |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1477994754 |
| Organization Name | HANCOCK REGIONAL HOSPITAL |
| Doing Business As | GREAT LAKES HEALTHCARE CENTER |
| Address | 2300 Great Lakes Dr, Dyer, IN 46311 |
| Phone Number | 219-322-3555 |
News Archive
Scientists have identified a gene they say is a strong candidate for involvement in premenstrual dysphoric disorder (PMDD) and other maladies associated with the natural flux in hormones during the menstrual cycle. In a paper to be published today in the Proceedings of the National Academy of Sciences, Rockefeller University researchers detail experiments in mice showing that a common human variant of the gene increases anxiety, dampens curiosity and tweaks the effects of estrogen on the brain, impairing memory.
Pittcon 2018, the 69th Conference and Exposition for Analytical Chemistry and Applied Spectroscopy, ended on March 1, in Orlando, Florida with an economic impact to the city estimated at $23 million. This global event brought together approximately 11,415 conferees and exhibitor personnel (official numbers to be released at the end of March).
Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the closing of a private financing by the existing investors of Quark totaling an aggregate of $10 million. The investors are funds of the prestigious SBI Holdings Group in Japan. In connection with the financing, Mr. Yoshitaka Kitao, CEO of SBI Holdings, Inc. and Mr. Robert Takeuchi, Director of SBI Investment Co., Ltd. will become members of the Quark board of directors.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Scientists have identified a gene they say is a strong candidate for involvement in premenstrual dysphoric disorder (PMDD) and other maladies associated with the natural flux in hormones during the menstrual cycle. In a paper to be published today in the Proceedings of the National Academy of Sciences, Rockefeller University researchers detail experiments in mice showing that a common human variant of the gene increases anxiety, dampens curiosity and tweaks the effects of estrogen on the brain, impairing memory.
Pittcon 2018, the 69th Conference and Exposition for Analytical Chemistry and Applied Spectroscopy, ended on March 1, in Orlando, Florida with an economic impact to the city estimated at $23 million. This global event brought together approximately 11,415 conferees and exhibitor personnel (official numbers to be released at the end of March).
Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the closing of a private financing by the existing investors of Quark totaling an aggregate of $10 million. The investors are funds of the prestigious SBI Holdings Group in Japan. In connection with the financing, Mr. Yoshitaka Kitao, CEO of SBI Holdings, Inc. and Mr. Robert Takeuchi, Director of SBI Investment Co., Ltd. will become members of the Quark board of directors.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 7.65 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.37 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 64.36 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 41.38 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.93 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 75.2 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 7.85 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 26.79 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.02 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 10.17 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 15 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 11.6 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 85.65 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 86.46 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 47.4 | 82.93 |
News Archive
Scientists have identified a gene they say is a strong candidate for involvement in premenstrual dysphoric disorder (PMDD) and other maladies associated with the natural flux in hormones during the menstrual cycle. In a paper to be published today in the Proceedings of the National Academy of Sciences, Rockefeller University researchers detail experiments in mice showing that a common human variant of the gene increases anxiety, dampens curiosity and tweaks the effects of estrogen on the brain, impairing memory.
Pittcon 2018, the 69th Conference and Exposition for Analytical Chemistry and Applied Spectroscopy, ended on March 1, in Orlando, Florida with an economic impact to the city estimated at $23 million. This global event brought together approximately 11,415 conferees and exhibitor personnel (official numbers to be released at the end of March).
Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the closing of a private financing by the existing investors of Quark totaling an aggregate of $10 million. The investors are funds of the prestigious SBI Holdings Group in Japan. In connection with the financing, Mr. Yoshitaka Kitao, CEO of SBI Holdings, Inc. and Mr. Robert Takeuchi, Director of SBI Investment Co., Ltd. will become members of the Quark board of directors.
› Verified 3 days ago
Great Lakes Healthcare Center Location: 2300 Great Lakes Dr, Dyer, Indiana 46311 Phone: (219) 322-3555 | |
Dyer Nursing And Rehabilitation Center Location: 601 Sheffield Ave, Dyer, Indiana 46311 Phone: (219) 322-2273 | |